VHVida Veronica Ruíz Herrera

Vida Veronica Ruíz Herrera

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Vida Veronica Ruíz Herrera has a total of 20 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Multifactorial determinants of lost to follow-up in antiretroviral therapy: evidence from a case–control study in Mexico

    by Luis Eduardo del Moral Trinidad, Luz Alicia González Hernández, Jaime Federico Andrade Villanueva, Fernando Amador Lara, Sergio Zúñiga Quiñones, Vida Verónica Ruíz Herrera, Adriana Valle Rodríguez, Karina Sánchez Reyes, Monserrat Alvarez Zavala, Guillermo Adrián Alanis Sánchez, et al.

    Loss to follow-up (LTFU) remains a major challenge in achieving sustained HIV care. Understanding individual and structural factors influencing disengagement is essential to improve retention, particularly in low- and middle-income settings. This study aimed to identify predictors of LTFU among adults receiving antiretroviral therapy (ART) in western Mexico. A case-control study was conducted among adults with HIV treated at a tertiary hospital. Cases met the national definition of LTFU (≥ 90 days beyond the expected clinic visit or pharmacy refill), while controls were retained patients during the same period. A total of 919 participants were included (148 LTFU, 771 retained). Multivariable logistic regression identified factors associated with LTFU. Median age was 42 years (IQR 34, 51) and 88% were male. The multivariable analysis identified that age was associated with lower risk of LTFU (adjusted odds ratio [aOR] per year, 0.94; 95% CI, 0.91-0.96). Secondary ART resistance (aOR, 4.03; 95% CI, 1.59-9.99), hard-drug use (aOR, 2.57; 95% CI, 1.68-3.93), psychiatric disorders (aOR, 3.58; 95% CI, 2.23-5.72), lower educational level (≥ upper secondary vs. no formal education/primary: aOR, 2.30; 95% CI, 1.34-3.94), emergency department visits (aOR, 2.63; 95% CI, 1.72-4.04), and years living with HIV (aOR per year, 1.06; 95% CI, 1.02-1.10) were associated with higher odds of LTFU. These findings highlight the role of psychosocial and structural determinants of LTFU, underscoring the need for integrated interventions addressing education, mental health, and substance use to improve retention in HIV care in Mexico.

  • Open Access

    Simplified Medication Adherence Questionnaire (SMAQ) for People Living With HIV in a National Hospital in Mexico: Instrument Validation Study

    by Luis Eduardo Del Moral Trinidad, Luz Alicia González Hernández, Jaime Federico Andrade Villanueva, Pedro Martínez-Ayala, Adriana Valle Rodríguez, Vida Veronica Ruíz Herrera, José Adán Vizcaíno Résendiz, Melva Guadalupe Herrera Godina, Sergio Dominguez-Lara

    Background: Adherence to antiretroviral therapy is a critical component in achieving viral suppression in people living with HIV in addition to increasing overall quality of life. Several indirect methods have been used to measure adherence including the Simplified Medication Adherence Questionnaire (SMAQ). Objective: The objective of this study is to evaluate the reliability and validity of the SMAQ in men living with HIV/AIDS attending a Mexican national hospital. Methods: A cross-sectional analytical design study was carried out in a Mexican National Hospital in Jalisco, including men aged >18 years with at least 3 months of antiretroviral treatment, excluding those with cognitive difficulties in answering the survey. A minimum sample size was calculated to detect the contribution of the variables within the model. The analysis included descriptive tests, confirmatory factor analysis, reliability and validity assessment, correlation between adherence and viral load, and association between viral load and adherence. Results: The final analysis included a total of 260 patients with a mean age of 43 (SD 12) years and an average of 8.97 (SD 6.33) years on antiretroviral treatment. The SMAQ showed sufficient structural validity (comparative fit index=1, root-mean-square error of approximation=0, 90% CI 0-0.085) with satisfactory factor loadings on most questions except item 2 (Do you always take your medication at the prescribed time?). The reliability of the scale is acceptable (Cronbach α=0.702, ω=0.718). Adherence correlated with viral load significantly but not with recent TCD4 lymphocyte levels. Patients classified as adherent were three times more likely to be undetectable than nonadherent patients (odds ratio 3.31, 95% CI 1.13-9.64, P=.04). Conclusions: The SMAQ represents an adequate tool to assess adherence in men living with HIV in the Mexican context, this will contribute to this study and compression of adherence to establish future intervention programs.


  • Open Access

    Simplified Medication Adherence Questionnaire (SMAQ) for People Living With HIV in a National Hospital in Mexico: Instrument Validation Study (Preprint)

    by Luis Eduardo Del Moral Trinidad, Luz Alicia González Hernández, Jaime Federico Andrade Villanueva, Pedro Martínez-Ayala, Adriana Valle Rodríguez, Vida Veronica Ruíz Herrera, José Adán Vizcaíno Résendiz, Melva Guadalupe Herrera Godina, Sergio Dominguez-Lara

    BACKGROUND Adherence to antiretroviral therapy is a critical component in achieving viral suppression in people living with HIV in addition to increasing overall quality of life. Several indirect methods have been used to measure adherence including the Simplified Medication Adherence Questionnaire (SMAQ). OBJECTIVE The objective of this study is to evaluate the reliability and validity of the SMAQ in men living with HIV/AIDS attending a Mexican national hospital. METHODS A cross-sectional analytical design study was carried out in a Mexican National Hospital in Jalisco, including men aged >18 years with at least 3 months of antiretroviral treatment, excluding those with cognitive difficulties in answering the survey. A minimum sample size was calculated to detect the contribution of the variables within the model. The analysis included descriptive tests, confirmatory factor analysis, reliability and validity assessment, correlation between adherence and viral load, and association between viral load and adherence. RESULTS The final analysis included a total of 260 patients with a mean age of 43 (SD 12) years and an average of 8.97 (SD 6.33) years on antiretroviral treatment. The SMAQ showed sufficient structural validity (comparative fit index=1, root-mean-square error of approximation=0, 90% CI 0-0.085) with satisfactory factor loadings on most questions except item 2 (Do you always take your medication at the prescribed time?). The reliability of the scale is acceptable (Cronbach α=0.702, ω=0.718). Adherence correlated with viral load significantly but not with recent TCD4 lymphocyte levels. Patients classified as adherent were three times more likely to be undetectable than nonadherent patients (odds ratio 3.31, 95% CI 1.13-9.64, P=.04). CONCLUSIONS The SMAQ represents an adequate tool to assess adherence in men living with HIV in the Mexican context, this will contribute to this study and compression of adherence to establish future intervention programs.

  • Pilot study on the efficacy and safety of berberine in people with metabolic syndrome and human immunodeficiency virus infection

    by Vida V Ruiz-Herrera, Shaúl A Navarro-Lara, Jaime F Andrade-Villanueva, Monserrat Alvarez-Zavala, Karina Sánchez-Reyes, Marcela Toscano-Piña, Anibal S Méndez-Clemente, Pedro Martínez-Ayala, Adriana Valle-Rodríguez, Luz A González-Hernández

    Background: Antiretroviral therapy has increased the life expectancy of people living with HIV. However, this increase is not free of comorbidities, and metabolic syndrome is one of the most prevalent. Berberine is an alkaloid nutraceutical that has been shown to ameliorate metabolic disorders such as prediabetes, polycystic ovary syndrome, and non-alcoholic fatty liver disease. However, it has not been tested in HIV infection. Therefore, we conducted a randomized controlled trial to evaluate the efficacy of berberine in improving metabolic syndrome. Methods and results: In this double-blind, placebo-controlled trial, adults living with HIV under virological suppression and metabolic syndrome received either berberine 500 mg TID or placebo for 20 weeks. The primary outcomes were a composite of weight reduction, insulin resistance decrease, and lipid profile improvement. A total of 43 participants were randomized (22 in the berberine group and 21 in the placebo group); 36 participants completed the follow-up and were analyzed. The berberine group showed a reduction in weight and body mass index, lower insulin resistance, and a reduction in TNF-alpha. The control group had higher total cholesterol, c-LDL, and IL-6 concentration. Conclusion: In people living with HIV under virological suppression, berberine was safe and improves clinical and biochemical components of metabolic syndrome. However, further studies with more participants and longer intervention periods need to be explored.